A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

Mu, Qiwen; Johnson, Kevin A.; Morgan, Paul S.; Grenesko, Emily L.; Molnar, Christine E.; Anderson, Berry; Nahas, Ziad; Kozel, F. Andrew; Köse, Samet; Knable, Michael B.; Fernandes, Prabhavathi; Nichols, David E.; Mailman, Richard B.; George, Mark S.

doi:10.1016/j.schres.2007.03.033

Cited by 79 publications

(47 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this recent work, dihydrexidine did not produce signifi cant hypotension [ 41 ]. Functional neuroimaging in patients receiving dihydrexidine revealed enhanced perfusion in D1-populated cortical regions relevant to cognition [ 42 ].…”

Section: Drug Treatment Specifi Cally Targeting Cognitive Impairmentmentioning

confidence: 72%

Better pharmacotherapy for schizophrenia: What does the future hold?

Webber¹,

Marder²

2008

Curr Psychiatry Rep

View full text Add to dashboard Cite

Despite the expansion of available antipsychotic drugs over the past 50 years, functional outcomes for individuals with schizophrenia have not markedly improved. These agents are efficacious for psychosis but do not adequately address other core domains of schizophrenia psychopathology, namely negative symptoms and cognitive impairment, which have a greater impact on functional outcomes, including vocational or academic performance and interpersonal relationships. In addition, treatment-refractory psychosis still precludes functional improvement in many patients. Schizophrenia is a clinical syndrome consisting of these domains, which likely have some disparities in their respective pathophysiologies. This suggests that drug development should look to other molecular targets besides the D2 receptor, which characterizes the mechanism of available medications for schizophrenia. In this report, we review novel pharmacologic approaches that aim to specifically address each individual domain of schizophrenia. The goal of this future pharmacotherapy strategy is to advance outcomes beyond psychosis remission and toward functional recovery.

show abstract

Section: Drug Treatment Specifi Cally Targeting Cognitive Impairmentmentioning

confidence: 72%

Better pharmacotherapy for schizophrenia: What does the future hold?

Webber¹,

Marder²

2008

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…Dopamine released from dendritic cells has been shown to display a novel function in terms of inducing the differentiation of Th17 cells and causing experimental autoimmune encephalitis (Nakano et al, 2008) and antigen-induced neutrophilic airway inflammation (Nakagome et al, 2011). The drugs targeting dopamine D 1 receptors may be useful in the treatment of a wide range of disorders, including Parkinson's disease (Rascol et al, 2001), schizophrenia (Mu et al, 2007), hypertension (Granda et al, 2014), allergy and autoimmune diseases (Nakagome et al, 2011;Nakano et al, 2008 ).…”

Section: Discussionmentioning

confidence: 99%

The ligand binding ability of dopamine D1 receptors synthesized using a wheat germ cell-free protein synthesis system with liposomes

Arimitsu

Ogasawara

Takeda

et al. 2014

European Journal of Pharmacology

View full text Add to dashboard Cite

“…Dihydrexidine (DAR-0100) is a D1 DA receptor agonist which was used in a small phase I, singledose, placebo-controlled, within-subject magnetic resonance imaging (MRI) perfusion study in 20 subjects with schizophrenia or Parkinson's disease. DAR-0100 was well tolerated [66] and increased cerebral perfusion was noted, with DAR-0100 generating increases in prefrontal perfusion compared to placebo [67]. However, the physical characteristics of DAR-0100, specifically its lack of oral absorption, have limited its usefulness as a drug probe.…”

Section: D1 Dopamine Agonistsmentioning

confidence: 99%

Treating Impaired Cognition in Schizophrenia

Ibrahim¹,

Tamminga²

2012

CPB

View full text Add to dashboard Cite

Cognitive impairment is a core feature of schizophrenia that substantially accounts for poor functional outcomes associated with this disease in areas such as work, independent living and social relationships. Until recently, drug development in schizophrenia has focused on developing compounds that mainly target the positive psychotic symptoms of the illness. Although current antipsychotic drugs treat psychosis in schizophrenia rather well, their impact on cognitive dysfunction is minimal. In recent years there has been growing interest in developing novel treatments for cognitive deficits in schizophrenia. In this review we discuss pharmacologic strategies considered most likely to improve cognition. These putative molecular targets include receptors for acetylcholine, dopamine, glutamate, g-aminobutyric acid (GABA), serotonin and histamine. In addition, we propose that not only pharmacological, but also psychological treatments should be considered to enhance cognition in schizophrenia.

show abstract

A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia

Cited by 79 publications

References 51 publications

Better pharmacotherapy for schizophrenia: What does the future hold?

Better pharmacotherapy for schizophrenia: What does the future hold?

The ligand binding ability of dopamine D1 receptors synthesized using a wheat germ cell-free protein synthesis system with liposomes

Treating Impaired Cognition in Schizophrenia

Contact Info

Product

Resources

About